Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs

Colloids and Surfaces B: Biointerfaces

Volumn 101, Issue , 2013, Pages 434-441

  Mehta, S K ^a   Jindal, Neha ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Anti TB drugs; Dissolution; Entrapment; Niosomes; Stability; Tyloxapol

Indexed keywords

ANTI-TB DRUGS; BI-LAYER; BIOCOMPATIBLE SURFACTANTS; DRUG DELIVERY SYSTEM; ENTRAPMENT; FICKIAN DIFFUSION MECHANISM; FOURIER TRANSFORM INFRARED; HEAD GROUPS; HYDROPHILIC DRUGS; IN-VITRO DISSOLUTION; KINETIC MODELS; LOADING EFFICIENCY; NIOSOMES; NON-FICKIAN; PHYSIOLOGICAL CONDITION; PYRAZINAMIDE; REGRESSION COEFFICIENT; RELEASE BEHAVIORS; RELEASE MECHANISM; SUSTAINED RELEASE; TEM IMAGES; TYLOXAPOL; VERSATILE SYSTEM;

CONVERGENCE OF NUMERICAL METHODS; DISSOLUTION; DRUG DELIVERY; DRUG PRODUCTS; SPECTROSCOPIC ANALYSIS; TUBES (COMPONENTS);

DRUG DOSAGE;

ISONIAZID; NIOSOME; PYRAZINAMIDE; RIFAMPICIN; TYLOXAPOL NIOSOME; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ARTICLE; BILAYER MEMBRANE; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; KINETICS; LOADING DRUG DOSE; PARTICLE SIZE; PHOTOLUMINESCENCE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ABSORPTION; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; HYDROGEN-ION CONCENTRATION; ISONIAZID; KINETICS; LIPOSOMES; LUMINESCENCE; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; POLYETHYLENE GLYCOLS; PYRAZINAMIDE; PYRENES; RIFAMPIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS;

EID: 84865526076     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.07.006     Document Type: Article

References (45)

1. Du Toit L.C., Pillay V., Danckwerts M.P. Respir. Res. 2006, 7:118.
2. http://www.health.state.mn.us/divs/idepc/diseases/tb/phaseschart.html.
3. Klaudt K. The Political Causes and Solutions of the Current Tuberculosis Epidemic 1998, Macmillan.
4. International Union Against Tuberculosis and Lung Disease (The Union).
5. Smith I. Clin. Microbiol. Rev. 2003, 16:463.
6. Mariappan T.T., Singh S. Int. J. Tuberc. Lung Dis. 2003, 7:797.
7. Mariappan T.T., Singh S. Clin. Res. Regul. Aff. 2006, 23:1.
8. Collett A., Tanianis-Hughes J., Warhurst G. Biochem. Pharmacol. 2004, 68:783.
9. Dye C. Lancet 2006, 367:938.
10. Maggi N., Vigevani A., Gallo G.G., Pasqualucci C.R. J. Med. Chem. 1968, 11:936.
11. Gürsoy A., Kut E., özki{dotless}ri{dotless}ml S. Int. J. Pharm. 2004, 271:115.
12. Mitchison D.A. Tubercle 1985, 66:219.
13. Zhang Y., Mitchison D. Int. J. Tuberc. Lung Dis. 2003, 7:6.
14. Prabakaran D., Singh P., Jaganathan K.S., Vyas S.P. J. Control. Release 2004, 95:239.
15. Ristsehel W.A. Methods Find. Exp. Clin. Pharmacol. 1991, 13:205.
16. Gabizon A., Goren D., Cohen R., Barenholz Y. J. Control. Release 1998, 53:275.
17. Navalakhe R.M., Nandedkar T.D. Indian J. Exp. Biol. 2007, 45:160.
18. Sato Y., Kiwada H., Kato Y. Chem. Pharm. Bull. 1986, 34:4244.
19. Florence A.T., Attwood D. Physicochemical Principles of Pharmacy 1998, Macmillan, London. 3rd ed.
20. Hao Y., Zhao F., Li N., Yang Y., Li K. Int. J. Pharm. 2002, 244:73.
21. Mehta S.K., Jindal N., Kaur G. Colloids Surf. B 2011, 87:173.
22. Vostrikov V.V., Selishcheva A.A., Sorokoumova G.M., Shakina Y.N., Shvets V.I., Savel'ev O.Y., Polshakov V.I. Eur. J. Pharm. Biopharm. 2008, 68:400.
23. Kalynasundaram K., Thomas J.K. J. Am. Chem. Soc. 1977, 99:2039.
24. Liu T., Guo R. Colloids Surf. A 2007, 295:130.
25. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., Ahmad I. Eur. J. Pharm. Biopharm. 2005, 59:177.
26. Zhang L., Sun X., Zhang Z.R. Drug Deliv. 2005, 12:289.
27. Dai H., Chen Q., Qin H., Guan Y., Shen D., Hua Y., Tang Y., Xu J. Macromolecules 2006, 39:6584.
28. Washington C. Int. J. Pharm. 1990, 58:1.
29. Scott H. J. Colloid Interface Sci. 1998, 205:496.
30. Regev O., Zana R. J. Colloid Interface Sci. 1999, 210:8.
31. Westesen K. Int. J. Pharm. 1994, 102:91.
32. Westesen K., Koch M.H. Int. J. Pharm. 1994, 103:225.
33. Torchilin V.P., Trubetskoy V.S. Adv. Drug Deliv. Rev. 1995, 16:141.
34. Moghimi S.M., Szebeni J. Prog. Lipid Res. 2003, 42:463.
35. Desai K.G.H., Park H.J. Drug Dev. Res. 2005, 64:114.
36. Jelvehgari M., Nokhodchi A., Rezapour M., Valizadeh H. Indian J. Pharm. Sci. 2010, 72:72.
37. Vladimirov Y.A., Dobrezov G.E. Fluorescence Probes in Biological Membrane Studies 1980, Nauka Press, Moscow, p. 36.
38. Sikaris K.A., Thulborn K.R., Saywer W.H. Chem. Phys. Lipids 1981, 29:23.
39. Lissi E., Bianconi M.L., Do Amaral A.T., De Paula E., Blanch L.E.B., Schreier S. Biochim. Biophys. Acta 1990, 1021:46.
40. Matsuyama H., Tamura T., Kitamura Y. Sep. Purif. Technol. 1999, 16:181.
41. Xu D., Loo L.S., Wang K. J. Appl. Polym. Sci. 2011, 122:427.
42. Woo B.H., Kostanski J.W., Gebrekidan S. J. Control. Release 2001, 75:307.
43. Ellenhorn M.J., Barceloux D.G. Medical Toxicology: Diagnosis and Treatment of Human Poisoning 1988, vol. 29. Elsevier, Amsterdam.
44. Balasubramaniam A., Anil Kumar V., Pillai K.S. Drug Dev. Ind. Pharm. 2002, 28:1181.
45. Sworakowski J., Matczyszyn K. Acta Phys. Pol. A 2007, 112:S-S153.